Health Genentech’s Tecentriq Delivers Promising Results in Bladder Cancer Treatment Genentech has reported significant findings from its Phase III IMvigor011 study, which evaluated the efficacy of its drug, Tecentriq (atezolizumab), as an adjuvant treatment... Editorial5 hours ago